Home » Newsletters » BioWorld Science

BioWorld Science

June 26, 2008

View Archived Issues

Antisense oligonucleotide microsphere vaccine prevents type 1 diabetes in vivo

Novel antiarthritic compounds reported in recent patents

Avapro to soon be launched in Japan for the treatment of hypertension

Emisphere and Novo Nordisk to collaborate on development of oral GLP-1 receptor agonists

Ovation to in-license ATryn in the U.S.

Akesis to initiate 13-week animal study for AKP- 020

AVE-1642 well tolerated in advanced solid tumor patients

BioGeneriX and Neose initiate phase II GlycoPEG-GCSF trial

Mechanism-based target modulation evidenced with SNS-032 treatment

FDA approves PrandiMet, a repaglinide and metformin fixed-dose tablet

Tanezumab appears safe and effective in phase II study in patients with osteoarthritic pain

Genmab initiates phase I/II zalutumumab with radiotherapy for advanced head and neck cancer

Vaccination with ChimeriVax-Dengue safe and immunogenic in phase II study

Albiglutide safe and well tolerated in early clinical studies

Elacyt gets orphan drug designation in U.S.

CuraGen commences phase II CR011-vcMMAE trial in advanced breast cancer

Recent Santen patents describe novel agents for metabolic disorders

Abbott patents DGAT-1 inhibitors

FDA approves Kinrix combination vaccine for children

Morria initiates phase II multi-dose MRX-4 study in allergic rhinitis

New Aptivus solution approved for treatment-experienced pediatric HIV patients

UCB reports results preliminary results from phase IIa lacosamide trial

Nymox presents new data for NX-1207 in benign prostatic hyperplasia

European Commission approves Roche's shortened Pegasys regimen for HCV

FDA Advisory Committee recommends approval of tolvaptan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...